ヘルスケア
ヘルスケアは、グローバルトレンド、技術・革新及び各国の市場特性、人口動態や規制当局に影響を受けるセクターです。
アジアにおける投資及び業界再編に影響を与える主な要因は:
- 可処分所得の増加、急速に変化する多様な人口動態;
- 地理的及び生理学的な特性;
- 政府・行政支援による医療システムの発展;
- メディカル及びライフサイエンステクノロジーに精通するイノベーターの出現;
- 世界の成長市場に対する需要が拡大する中、アジアと欧米の間では、地域企業による双方向M&Aの動きが加速
当社のグローバル・ヘルスケアチームは、企業、金融スポンサー、起業家の皆様に対し、各地域に根ざした高度な知見とグローバルな視点、豊富な取引実績を融合させたアドバイザリーサービスを提供しています。
対応領域は、ヘルスケアサービス、医療機器、製薬・バイオテクノロジー、製薬業務のアウトソーシング(CRO・CDMO)、コンシューマーヘルス、アニマルヘルスおよび植物・生命科学など、多岐にわたります。

Andrew Huntley
Managing Partner, Head of Healthcare

Sanjay Singh
Partner, Head of BDA India, Co-Head Asia Healthcare

Sophia Wu
Senior Advisor

invested in

a portfolio company of

2025

has divested strategic stake to


2025

divested majority stake in

to

2024

acquired majority stake in


2024

has been acquired by


2023

received investment from


2023

a subsidiary of

has acquired

2022

a portfolio company of

has been acquired by

2022

agreed to divest East Syracuse, New York facility to


2022

has sold minority stake to


2022

a portfolio company of

has been acquired by

2022

investment from


2021

has been acquired by


2021

a portfolio company of

has been acquired majority stake by

2021

a portfolio company of

has been acquired by

2021

divested majority stake to


DCP Capital
2021

agreed to divest Couvet, Switzerland facility to WuXi AppTec


2021

raised Series B round from


2021

backed by

has been acquired by

2020

divested Escientia Life Sciences to Deccan Fine Chemicals


2020

divested significant stake in

Kehua Bio-Engineering to Gree Real Estate
2020

majority sale
2019

LAP Lasers a portfolio company of

has been acquired by

2019

divested majority stake to


2019

a portfolio company of

has been acquired by

AGIC and Humanwell
2017

recapitalized majority by


2017

divested CMC Biologics to


2017

has been acquired by a Japanese chemicals & life science company
2016

acquired Adval Tech Medical (Suzhou) and Omni Manufacturing (Mexico)
2013

divested Radiant Research Inc, US-based clinical research company

2012



















